PFF Help Center(844) 825-5733

To navigate the following site navigation expect to utilize the tab key to move through items sequentially. The spacebar or enter keys can be utilized to interact with items that open sub-navigation.

Drug

LTI-03

Status:

Phase 2

Condition:

Idiopathic Pulmonary Fibrosis

Intervention Type:

Inhaled Drug

Funder Type:

Industry

Drug Details

LTI-03 is an investigational inhaled synthetic peptide derived from Caveolin-1 (Cav-1) that blocks pro-fibrotic signaling to reduce lung scarring and helps preserve alveolar epithelial cells, which are important for lung repair and regeneration.

Study Purpose

This is a randomized, double-blind, placebo-controlled, multi-center study that evaluates the safety and efficacy of LTI-03 compared to placebo in patients diagnosed with IPF within the last five years.